Pressure Biosciences (OTCMKTS: PBIO) is one of 25 public companies in the “Analytical instruments” industry, but how does it weigh in compared to its rivals? We will compare Pressure Biosciences to related companies based on the strength of its analyst recommendations, valuation, risk, profitability, earnings, institutional ownership and dividends.
Institutional and Insider Ownership
59.2% of shares of all “Analytical instruments” companies are held by institutional investors. 15.9% of Pressure Biosciences shares are held by insiders. Comparatively, 15.9% of shares of all “Analytical instruments” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
This is a breakdown of recent ratings and target prices for Pressure Biosciences and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Pressure Biosciences Competitors||185||921||1288||66||2.50|
As a group, “Analytical instruments” companies have a potential downside of 3.38%. Given Pressure Biosciences’ rivals higher possible upside, analysts plainly believe Pressure Biosciences has less favorable growth aspects than its rivals.
Volatility & Risk
Pressure Biosciences has a beta of 1.12, suggesting that its share price is 12% more volatile than the S&P 500. Comparatively, Pressure Biosciences’ rivals have a beta of 1.45, suggesting that their average share price is 45% more volatile than the S&P 500.
Earnings & Valuation
This table compares Pressure Biosciences and its rivals gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Pressure Biosciences||$2.46 million||-$9.70 million||-0.16|
|Pressure Biosciences Competitors||$1.14 billion||$146.92 million||12.54|
Pressure Biosciences’ rivals have higher revenue and earnings than Pressure Biosciences. Pressure Biosciences is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
This table compares Pressure Biosciences and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Pressure Biosciences Competitors||-212.02%||-25.29%||-11.33%|
Pressure Biosciences rivals beat Pressure Biosciences on 8 of the 10 factors compared.
Pressure Biosciences Company Profile
Pressure BioSciences, Inc. develops pressure cycling technology (PCT) solutions. Its PCT technology uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control the actions of molecules in biological samples, such as cells and tissues from human, animal, plant, and microbial sources. The company offers Barocycler instrumentations, including Barocycler 2320EXT, Barozyme-HT48, Barocycler NEP3229, HUB440, HUB880, and The Shredder SG3. It also distributes cell disruption equipment, parts, and consumables. In addition, the company offers Barocycler consumable products, such as PCT MicroTubes, PCT-MicroCaps, PCT-Micro-Pestle, PULSE Tubes, and BaroFlex 8-well Processing Strips, as well as application specific kits. Pressure BioSciences, Inc. serves researchers at academic laboratories; government agencies; and biotechnology, pharmaceutical, and other life sciences institutions in the United States, Europe, and Asia. Pressure BioSciences, Inc. has a collaboration with NutraFuels, Inc. for the development of water-soluble Nanoemulsion-based nutraceuticals. The company was formerly known as Boston Biomedica, Inc. Pressure BioSciences, Inc. was founded in 1978 and is based in South Easton, Massachusetts.
Receive News & Ratings for Pressure Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pressure Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.